In general, the prognosis outcome of non-mCRC patients is directed by the TNM-stage, which provides the prognostic information with approximately 93% 5-year stage-specific survival rate for stage I, 84% for stage II, and 83% for stage III [40] and is influenced by clinicopathological parameters such as vascular invasion, poor differentiation, tumor size and serum tumor markers (i.e., carcinoembryonic antigen, CEA). The gene discussed is CEACAM5; the disease is neoplasm.